Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer

Moch, 2015 Amin, 2009, Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications, Mod. Pathol., 22, S96, 10.1038/modpathol.2009.26 Nigwekar, 2008, The many faces of urothelial carcinoma: an update with an emphasis on recently described variants, Adv. Anat. Pathol., 15, 218, 10.1097/PAP.0b013e31817d79b9 Wasco, 2007, Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection, Urology, 70, 69, 10.1016/j.urology.2007.03.033 Amin, 1994, Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma, Am. J. Surg. Pathol., 18, 1224, 10.1097/00000478-199412000-00005 Al-Ahmadie, 2018, Updates on the genetics and molecular subtypes of urothelial carcinoma and select variants, Surg. Pathol. Clin., 11, 713, 10.1016/j.path.2018.07.011 Laé, 2010, Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients, Ann. Oncol., 21, 815, 10.1093/annonc/mdp488 Hussain, 2007, National cancer institute: trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II national cancer institute trial, J. Clin. Oncol., 25, 2218, 10.1200/JCO.2006.08.0994 Powles, 2017, Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer, J. Clin. Oncol., 35, 48, 10.1200/JCO.2015.66.3468 Li, 2015, Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma, Target. Oncol., 10, 355, 10.1007/s11523-014-0341-x Isharwal, 2018, Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma, Hum. Pathol., 77, 63, 10.1016/j.humpath.2018.03.015 Wolff, 2018, Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of American pathologists clinical practice guideline focused update, J. Clin. Oncol., 36, 2105, 10.1200/JCO.2018.77.8738 Ma, 2014, HER2 mRNA status contributes to the discrepancy between gene amplification and protein overexpression in gastric cancer, Dig. Dis. Sci., 59, 328, 10.1007/s10620-013-2925-1 Behzatoğlu, 2018, Human epidermal growth factor receptor 2 overexpression in micropapillary and other variants of urothelial carcinoma, Eur. Urol. Focus, 4, 399, 10.1016/j.euf.2016.06.007 Zinnall, 2018, Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype, Hum. Pathol., 80, 55, 10.1016/j.humpath.2018.05.022 Tschui, 2015, Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer, Virchows Arch., 466, 703, 10.1007/s00428-015-1729-4